Literature DB >> 22694972

Phosphorylation is the switch that turns PEA-15 from tumor suppressor to tumor promoter.

Florian Sulzmaier1, John Opoku-Ansah, Joe W Ramos.   

Abstract

Abnormal ERK signaling is implicated in many human diseases including cancer. This signaling cascade is a good target for the therapy of certain malignancies because of its important role in regulating cell proliferation and survival. The small phosphoprotein PEA-15 is a potent regulator of the ERK signaling cascade, and, by acting on this pathway, has been described to have both tumor-suppressor and tumor-promoter functions. However, the exact mechanism by which PEA-15 drives the outcome one way or the other remains unclear. We propose that the cellular environment is crucial in determining PEA-15 protein function by affecting the protein's phosphorylation state. We hypothesize that only unphosphorylated PEA-15 can act as a tumor-suppressor and that phosphorylation alters the interaction with binding partners to promote tumor development. In order to use PEA-15 as a prognostic marker or therapeutic target it is therefore important to evaluate its phosphorylation status.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22694972      PMCID: PMC3442804          DOI: 10.4161/sgtp.20021

Source DB:  PubMed          Journal:  Small GTPases        ISSN: 2154-1248


  36 in total

1.  PEA-15 mediates cytoplasmic sequestration of ERK MAP kinase.

Authors:  E Formstecher; J W Ramos; M Fauquet; D A Calderwood; J C Hsieh; B Canton; X T Nguyen; J V Barnier; J Camonis; M H Ginsberg; H Chneiweiss
Journal:  Dev Cell       Date:  2001-08       Impact factor: 12.270

Review 2.  The phosphatidylinositol 3-Kinase AKT pathway in human cancer.

Authors:  Igor Vivanco; Charles L Sawyers
Journal:  Nat Rev Cancer       Date:  2002-07       Impact factor: 60.716

3.  Protein kinase B/Akt binds and phosphorylates PED/PEA-15, stabilizing its antiapoptotic action.

Authors:  Alessandra Trencia; Anna Perfetti; Angela Cassese; Giovanni Vigliotta; Claudia Miele; Francesco Oriente; Stefania Santopietro; Ferdinando Giacco; Gerolama Condorelli; Pietro Formisano; Francesco Beguinot
Journal:  Mol Cell Biol       Date:  2003-07       Impact factor: 4.272

4.  The recruitment of Raf-1 to membranes is mediated by direct interaction with phosphatidic acid and is independent of association with Ras.

Authors:  M A Rizzo; K Shome; S C Watkins; G Romero
Journal:  J Biol Chem       Date:  2000-08-04       Impact factor: 5.157

5.  PEA15 impairs cell migration and correlates with clinical features predicting good prognosis in neuroblastoma.

Authors:  Joanna E Gawecka; Dirk Geerts; Jan Koster; Maisel J Caliva; Florian J Sulzmaier; John Opoku-Ansah; Randal K Wada; André S Bachmann; Joe W Ramos
Journal:  Int J Cancer       Date:  2012-01-31       Impact factor: 7.396

Review 6.  EGFR and cancer prognosis.

Authors:  R I Nicholson; J M Gee; M E Harper
Journal:  Eur J Cancer       Date:  2001-09       Impact factor: 9.162

7.  Regulation of expression of phospholipase D1 and D2 by PEA-15, a novel protein that interacts with them.

Authors:  Y Zhang; O Redina; Y M Altshuller; M Yamazaki; J Ramos; H Chneiweiss; Y Kanaho; M A Frohman
Journal:  J Biol Chem       Date:  2000-11-10       Impact factor: 5.157

8.  Recognition of ERK MAP kinase by PEA-15 reveals a common docking site within the death domain and death effector domain.

Authors:  Justine M Hill; Hema Vaidyanathan; Joe W Ramos; Mark H Ginsberg; Milton H Werner
Journal:  EMBO J       Date:  2002-12-02       Impact factor: 11.598

Review 9.  Ras family genes: an interesting link between cell cycle and cancer.

Authors:  M Macaluso; G Russo; C Cinti; V Bazan; N Gebbia; A Russo
Journal:  J Cell Physiol       Date:  2002-08       Impact factor: 6.384

10.  Protein kinase C (PKC)-alpha activation inhibits PKC-zeta and mediates the action of PED/PEA-15 on glucose transport in the L6 skeletal muscle cells.

Authors:  G Condorelli; G Vigliotta; A Trencia; M A Maitan; M Caruso; C Miele; F Oriente; S Santopietro; P Formisano; F Beguinot
Journal:  Diabetes       Date:  2001-06       Impact factor: 9.461

View more
  19 in total

1.  Integrin α5β1 and p53 convergent pathways in the control of anti-apoptotic proteins PEA-15 and survivin in high-grade glioma.

Authors:  G Renner; H Janouskova; F Noulet; V Koenig; E Guerin; S Bär; J Nuesch; F Rechenmacher; S Neubauer; H Kessler; A-F Blandin; L Choulier; N Etienne-Selloum; M Lehmann; I Lelong-Rebel; S Martin; M Dontenwill
Journal:  Cell Death Differ       Date:  2015-10-16       Impact factor: 15.828

2.  Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer.

Authors:  Masanori Kawakami; Lisa Maria Mustachio; Jaime Rodriguez-Canales; Barbara Mino; Jason Roszik; Pan Tong; Jing Wang; J Jack Lee; Ja Hye Myung; John V Heymach; Faye M Johnson; Seungpyo Hong; Lin Zheng; Shanhu Hu; Pamela Andrea Villalobos; Carmen Behrens; Ignacio Wistuba; Sarah Freemantle; Xi Liu; Ethan Dmitrovsky
Journal:  J Natl Cancer Inst       Date:  2017-06-01       Impact factor: 13.506

3.  Circadian expression and functional characterization of PEA-15 within the mouse suprachiasmatic nucleus.

Authors:  Kelin Wheaton; Sydney Aten; Lucas Sales Queiroz; Kyle Sullivan; John Oberdick; Kari R Hoyt; Karl Obrietan
Journal:  Eur J Neurosci       Date:  2018-02-19       Impact factor: 3.386

4.  Phosphorylation-regulated degradation of the tumor-suppressor form of PED by chaperone-mediated autophagy in lung cancer cells.

Authors:  Cristina Quintavalle; Stefania Di Costanzo; Ciro Zanca; Immaculada Tasset; Alessandro Fraldi; Mariarosaria Incoronato; Peppino Mirabelli; Maria Monti; Andrea Ballabio; Piero Pucci; Ana Maria Cuervo; Gerolama Condorelli
Journal:  J Cell Physiol       Date:  2014-10       Impact factor: 6.384

5.  Effects of anti-depressant treatments on FADD and p-FADD protein in rat brain cortex: enhanced anti-apoptotic p-FADD/FADD ratio after chronic desipramine and fluoxetine administration.

Authors:  M Julia García-Fuster; Jesús A García-Sevilla
Journal:  Psychopharmacology (Berl)       Date:  2016-06-03       Impact factor: 4.530

6.  Development of PEA-15 using a potent non-viral vector for therapeutic application in breast cancer.

Authors:  Xinhua Xie; Hailin Tang; Yanan Kong; Minqing Wu; Xiangsheng Xiao; Lu Yang; Jie Gao; Weidong Wei; Jangsoon Lee; Chandra Bartholomeusz; Naoto T Ueno; Xiaoming Xie
Journal:  Cancer Lett       Date:  2014-10-07       Impact factor: 8.679

7.  Antagonism of tumoral prolactin receptor promotes autophagy-related cell death.

Authors:  Yunfei Wen; Behrouz Zand; Bulent Ozpolat; Miroslaw J Szczepanski; Chunhua Lu; Erkan Yuca; Amy R Carroll; Neslihan Alpay; Chandra Bartholomeusz; Ibrahim Tekedereli; Yu Kang; Rajesha Rupaimoole; Chad V Pecot; Heather J Dalton; Anadulce Hernandez; Anna Lokshin; Susan K Lutgendorf; Jinsong Liu; Walter N Hittelman; Wen Y Chen; Gabriel Lopez-Berestein; Marta Szajnik; Naoto T Ueno; Robert L Coleman; Anil K Sood
Journal:  Cell Rep       Date:  2014-04-03       Impact factor: 9.423

8.  Structure of ERK2 bound to PEA-15 reveals a mechanism for rapid release of activated MAPK.

Authors:  Peter D Mace; Yann Wallez; Michael F Egger; Małgorzata K Dobaczewska; Howard Robinson; Elena B Pasquale; Stefan J Riedl
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

Review 9.  On the Quest of Cellular Functions of PEA-15 and the Therapeutic Opportunities.

Authors:  Yufeng Wei
Journal:  Pharmaceuticals (Basel)       Date:  2015-07-31

Review 10.  Phosphoprotein enriched in astrocytes (PEA)-15: a potential therapeutic target in multiple disease states.

Authors:  Fiona H Greig; Graeme F Nixon
Journal:  Pharmacol Ther       Date:  2014-03-20       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.